IRB approval paves way for Zelda to begin cannabis trials in …

Zelda Therapeutics ASX ZLD Institutional Review Board cannabis trial paediatric autism

Zelda Therapeutics (ASX: ZLD) has gained Institutional Review Board approval to trial its cannabinoid-based formulations on children suffering from autism, which was the final regulatory hurdle to jump before beginning the study.

The trial will be carried out at the Children’s Hospital of Philadelphia and involves observation and bioanalytical studies.

“We are very excited to be formally commencing this study in the US working alongside the Children’s Hospital of Philadelphia,” Zelda executive chairman Harry Karelis said.

“The high-calibre of Children’s Hospital of Philadelphia researchers and clinicians coupled with access to extensive

... read more at: